Amplification:Article Title: Nucleotide analogues
Article Snippet: “Hydroxy” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound A. .. “Commercial Inhibitor” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the NSP12/RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and the commercial inhibitor. ..
Article Title: Nucleotide analogues
Article Snippet: “Phospho” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound C. “Fluoro” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound B. .. “Hydroxy” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound A. .. “Commercial Inhibitor” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the NSP12/RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and the commercial inhibitor.
Article Title: Nucleotide analogues
Article Snippet: “RNA Primer” This lane was loaded with specific RNA primers of approximately 24 bases, obtained from Eurofins Genomics. .. “RNA Control” This lane was loaded with genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC) “Positive Control” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs. .. “No-Adenosine” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that no rATP was included.
Article Title: Nucleotide analogues
Article Snippet: “RNA Control” This lane was loaded with genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC) “Positive Control” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs. .. “No-Adenosine” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that no rATP was included. .. “Phospho” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound C. “Fluoro” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound B.
Article Title: Nucleotide analogues
Article Snippet: “No-Adenosine” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that no rATP was included. .. “Phospho” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound C. “Fluoro” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound B. .. “Hydroxy” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs in equimolar amounts, except that the standard amount for rATP was split 50:50 between rATP and Compound A.
Positive Control:
Article Title: Nucleotide analogues
Article Snippet: “RNA Primer” This lane was loaded with specific RNA primers of approximately 24 bases, obtained from Eurofins Genomics. .. “RNA Control” This lane was loaded with genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC) “Positive Control” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs. .. “No-Adenosine” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that no rATP was included.
Analogues:Article Title: Nucleotide analogues
Article Snippet: .. The tested compounds were adenosine analogues: The RNA polymerase used in the assays consisted of the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix), SARS-CoV-2 genomic RNA (2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC)), and the primers used in the assays consisted of (RNA or DNA) complementary to specific region, from Eurofins. .. PCR reactions used the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and dNTPs/rNTPs, respectively.
Control:Article Title: Nucleotide analogues
Article Snippet: “RNA Primer” This lane was loaded with specific RNA primers of approximately 24 bases, obtained from Eurofins Genomics. .. “RNA Control” This lane was loaded with genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC) “Positive Control” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs. .. “No-Adenosine” This lane was loaded with the amplification product obtained from amplifying genomic RNA from the 2019 Novel Coronavirus; Strain: 2019-nCoV/USA-WA1/2020 (Reference: ATCC-VR-1986D, ATCC), using the RdRp catalytic domain of RNA-directed RNA polymerase (Reference: PX-COV-P006, ProteoGenix) of SARS-CoV2 and the RNA primers (same as the lane “RNA Primer”), using the 10× First Strand Buffer and RNase Inhibitor from Amino Allyl MessageAmpTM II aRNA Amplification Kit (Reference: AM1753, Thermo), and rNTPs, in equimolar amounts, except that no rATP was included.
Sequencing:
Virus:
|
ATCC is a verified supplier 
ATCC manufactures this product 
